NanoVation Therapeutics Announces Multi-Year Partnership With Novo Nordisk To Develop Genetic Medicines Targeting Cardiometabolic And Rare Diseases, With Potential Payments Up To $600M And Tiered Royalties
Author: Benzinga Newsdesk | September 18, 2024 08:11am